openPR Logo
Press release

Bevacizumab Biosimilars Market 2024 -2033: Global Outlook, Industry Share, Business Growth And Major Players

Bevacizumab Biosimilars Market

Bevacizumab Biosimilars Market

The bevacizumab biosimilars market size has grown strongly in recent years. It will grow from $1.43 billion in 2023 to $1.55 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to patent expiry, cost containment in healthcare, increasing incidence of cancer, market competitiveness, patient access and affordability, biosimilar acceptance.

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising demand for cancer therapies, biosimilar development expertise, healthcare system pressures, biosimilar regulatory landscape, biosimilar interchangeability. Major trends in the forecast period include collaborations and partnerships, regulatory advancements and approvals, biosimilar development and innovation, market access strategies, biosimilar lifecycle management.

Market Overview -
Bevacizumab biosimilars are a type of medication that is highly similar to a reference biologic drug called bevacizumab. It is commonly used to inhibit the growth of new blood vessels in tumors, thereby slowing down their progression.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Growing Cancer Prevalence Fuels Bevacizumab Biosimilars Market Expansion
The rising prevalence of cancer cases is expected to propel the growth of the bevacizumab biosimilars market going forward. Cancer incidence refers to the number of new cancer cases in a specific population for a given period. Bevacizumab is a biologic that inhibits tumor angiogenesis, which can lead to tumor shrinkage and growth inhibition, and it is comparable to reference biologics in terms of efficacy and safety in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2022, according to reports published by Macmillan Cancer Support, a UK-based health care charity organization, it was anticipated that there were 3 million cancer patients in 2020, with that figure expected to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising prevalence of cancer cases drives the bevacizumab biosimilars market.

Competitive Landscape -
Major companies operating in the bevacizumab biosimilars market report are Cipla Limited, Reliance lifesciences Pvt. Ltd., Genentech Inc, Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., Abbvie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., EirGen Pharma Ltd., Allergan Plc., Apotex Inc., BioXpress Therapeutics SA, Celgene Corporation Co. Ltd., mAbxience SA

Advancing Product Innovation In Bevacizumab Biosimilars Market
Product innovation has emerged as a key trend gaining popularity in the bevacizumab biosimilars market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, launched a biosimilar called Abevmy (bevacizumab), which is a biosimilar like Roche's Avastin (bevacizumab). Abevmy has received approval from Health Canada for use across four oncology indications. The product offers efficacy, safety, and quality like the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF).

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Key Segments -
The bevacizumab biosimilars market covered in this report is segmented -
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bevacizumab Biosimilars Market 2024 -2033: Global Outlook, Industry Share, Business Growth And Major Players here

News-ID: 3453038 • Views:

More Releases from The Business research company

Evolving Market Trends In The Integrated Geophysical Services Industry: Enhancing Geophysical Surveys With Drones For Efficiency In Harsh Environments
Evolving Market Trends In The Integrated Geophysical Services Industry: Enhancin …
The Integrated Geophysical Services Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Integrated Geophysical Services Market Size During the Forecast Period? The integrated geophysical services market has experienced consistent growth in recent years, expected to rise from $2.35 billion in 2024 to
Global HR Advisory Services Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
Global HR Advisory Services Market: Key Trends, Market Share, Growth Drivers, An …
The HR advisory services market report describes and explains the HR advisory services market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global HR advisory services market reached a value of nearly $155.74 billion in 2024, having grown at a compound annual growth rate (CAGR) of 4.22% since
High Voltage Aluminium Electrolytic Capacitors Global Market Report 2025: Size, Trends, and Growth Insights for Global Expansion
High Voltage Aluminium Electrolytic Capacitors Global Market Report 2025: Size, …
The high voltage aluminum electrolytic capacitors report describes and explains the high voltage aluminum electrolytic capacitors market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global high voltage aluminum electrolytic capacitors market reached a value of nearly $4.10301 billion in 2024, having grown at a compound annual growth
Global Vertical Market Software Market: Key Trends, Market Share, Growth Drivers, and Forecast for 2025-2034
Global Vertical Market Software Market: Key Trends, Market Share, Growth Drivers …
The vertical market software report describes and explains the vertical market software market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global vertical market software market reached a value of nearly $152.61027 billion in 2024, having grown at a compound annual growth rate (CAGR) of 12.11% since 2019.

All 5 Releases


More Releases for Bevacizumab

Avastin (Bevacizumab) Market Report 2025-2034: Industry Overview, Trends, And Fo …
The Avastin (Bevacizumab) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Avastin (Bevacizumab) Market Size and Projected Growth Rate? In recent times, the market size for avastin (bevacizumab) has seen significant growth. Its growth is projected to continue from $7,251.35 million in 2024
Global Bevacizumab Biosimilars Market Outlook 2025-2034: Trends, Innovations, An …
The Bevacizumab Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Bevacizumab Biosimilars Market Size During the Forecast Period? There has been a robust expansion in the market size of bevacizumab biosimilars in the past few years. The market is projected to
Key Trend Reshaping the Bevacizumab Biosimilars Market in 2025: Advancing Produc …
What combination of drivers is leading to accelerated growth in the bevacizumab biosimilars market? An increasing number of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market in the future. The term cancer incidence refers to the tally of new cancer diagnoses within a certain demographic over a specified timeframe. Bevacizumab is a biologic agent that hinders tumor angiogenesis, resulting in the potential reduction and inhibition of
Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Majo …
What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market? In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase
Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Majo …
What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market? In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase
2020-2025: Bevacizumab Biosimilar Market Report Covers Growing Strategies Used B …
Business Industry Reports Research has recently announced a report on Global Bevacizumab Biosimilar Market based on the Healthcare Industry. The Bevacizumab Biosimilar Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2025. Global Bevacizumab Biosimilar Market overview: A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are